Microfluidic Peptide/mRNA Complexes for Pulmonary Delivery via Nebulisation

Study Background and Research Question

Messenger RNA (mRNA) and small interfering RNA (siRNA) have rapidly emerged as transformative platforms for therapeutic intervention, enabling precise modulation of cellular protein expression. The clinical translation of these modalities for lung diseases—including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and respiratory infections—demands a safe, efficient, and reproducible RNA delivery system that can withstand the physical stresses of pulmonary administration. Traditionally, lipid nanoparticles (LNPs) have dominated as non-viral RNA vectors, but their susceptibility to destabilisation by pulmonary surfactants and process-related stresses (e.g., during spray drying or nebulisation) has limited their utility in inhaled formulations. The core research question addressed by the study (Ma et al., 2025) is: Can peptide-based RNA complexes, fabricated via microfluidic mixing, offer a robust and efficient alternative for nebulised pulmonary delivery of mRNA and siRNA?

Key Innovation from the Reference Study

The principal innovation lies in the use of two cationic peptides—LAH4-L1 and PEG12KL4—as non-viral vectors for RNA complexation, combined with microfluidic mixing to ensure formulation reproducibility and control. This approach enables the generation of peptide/mRNA or peptide/siRNA complexes with defined physicochemical characteristics, suitable for aerosolisation. The study is among the first to systematically assess the impact of the nebulisation process on the particle size, RNA binding efficiency, and in vitro transfection ability of peptide/RNA complexes, providing critical insights into their potential as inhalable RNA therapeutics platforms (Ma et al., 2025).

Methods and Experimental Design Insights

The study implemented a multi-stage experimental workflow, focusing on both the fabrication and the post-nebulisation performance of peptide/RNA complexes:

• Microfluidic Mixing: LAH4-L1 and PEG12KL4 peptides were combined with either siRNA or mRNA using a controlled microfluidic device, allowing precise tuning of process parameters to achieve uniform complexation.
• Nebulisation: The resulting complexes were aerosolised using a vibrating mesh nebuliser, producing inhalable droplets with a mass median aerodynamic diameter below 5 μm—ideal for deep lung deposition.
• Physicochemical Characterisation: Particle size and RNA binding efficiency were quantified both before and after nebulisation using dynamic light scattering and electrophoretic methods.
• Functional Assessment: The transfection efficiency of the complexes was evaluated in A549 (alveolar epithelial) and BEAS-2B (bronchial epithelial) cell lines, modeling relevant pulmonary targets.

Importantly, the protocol allowed direct comparison of pre- and post-nebulisation samples, isolating the effect of aerosolisation stress on complex integrity and function.

Protocol Parameters

• Peptide/RNA complexation: Optimal peptide-to-RNA ratios were established empirically to maximize binding efficiency and minimize cytotoxicity.
• Microfluidic flow rates: Tuned to achieve consistent nanoparticle formation; typical flow rates in the study were calibrated for reproducibility.
• Nebulisation device: Vibrating mesh nebuliser selected for gentle aerosolisation, minimizing RNA degradation.
• Particle size target: Post-nebulisation hydrodynamic diameters of ~100 nm achieved, with aerosol droplet size <5 μm for effective pulmonary delivery.
• Transfection assay: Both A549 and BEAS-2B cells used to represent different pulmonary epithelial environments.

Core Findings and Why They Matter

The study's core findings underscore the viability of peptide-based RNA delivery systems for nebulised pulmonary administration:

• Particle Integrity: Nebulisation reduced the hydrodynamic size of RNA complexes to approximately 100 nm, but did not compromise RNA binding or delivery capability.
• Transfection Efficiency: Both LAH4-L1 and PEG12KL4 peptide complexes preserved their in vitro transfection efficiency after nebulisation, with no statistically significant reduction compared to pre-nebulisation controls (Ma et al., 2025).
• Device Suitability: The vibrating mesh nebuliser generated inhalable mists suitable for deep lung deposition, supporting broad patient applicability—including those unable to use breath-actuated inhalers.
• Clinical Implications: The findings suggest that peptide-based complexes can overcome key limitations of LNPs in pulmonary settings, such as instability in the presence of lung surfactants and mechanical stress.

This robust preservation of function post-nebulisation opens new avenues for inhaled RNA therapeutics, particularly for diseases where localized delivery and reduced systemic exposure are crucial.

Comparison with Existing Internal Articles

Internal resources such as ARCA Cy5 EGFP mRNA (5-moUTP): Dual-Mode mRNA Tracking and Precision Tools for Intracellular mRNA Tracking highlight the experimental challenges in quantifying mRNA delivery, localization, and translation in mammalian cells. These articles emphasize the value of 5-methoxyuridine modified mRNA and dual fluorescence labeling—technologies that directly address the need for sensitive, reproducible assessment of mRNA uptake and expression in complex systems.

While the reference study (Ma et al., 2025) focuses on the delivery vehicle and device compatibility, internal articles provide practical guidance on experimental readouts, such as using fluorescently labeled mRNA for delivery analysis and translation assays. This synergy—robust delivery strategies paired with high-sensitivity detection tools—forms the foundation for advancing both mechanistic and translational research in mRNA therapeutics.

Limitations and Transferability

Despite the promising results, the study has several limitations:

• In Vivo Validation: The work is restricted to in vitro models (A549 and BEAS-2B cells); in vivo studies are needed to confirm pulmonary deposition, distribution, and therapeutic efficacy.
• RNA Types: Although both siRNA and mRNA were tested, the study does not explore the full spectrum of chemically modified RNAs (e.g., 5-methoxyuridine modified mRNA), leaving open questions about immune recognition and stability in vivo.
• Long-Term Effects: Potential cumulative toxicity, immunogenicity, and mucociliary clearance of peptide complexes remain to be studied.
• Formulation Generalizability: While microfluidic mixing offers reproducibility, scaling up for clinical manufacturing and regulatory acceptance will require further standardisation.

Nonetheless, the approach demonstrates high transferability to research workflows focused on optimizing mRNA delivery and assessing translation efficiency—particularly when paired with advanced fluorescent mRNA tracking tools.

Why this cross-domain matters, maturity, and limitations

The transition from traditional LNP-based pulmonary mRNA delivery to peptide-mediated, microfluidic-fabricated formulations represents a significant cross-domain advance. This bridge is critical for expanding mRNA therapeutics beyond injectable vaccines toward localised, inhaled treatments for a range of pulmonary diseases. However, the maturity of peptide-based vectors in clinical settings is still nascent, and further research is crucial to fully characterise their long-term safety and efficacy in vivo.

Research Support Resources

To support researchers in implementing and monitoring peptide or non-viral mRNA delivery workflows, reagents such as ARCA Cy5 EGFP mRNA (5-moUTP) (SKU R1009) are available. This 5-methoxyuridine modified mRNA is covalently labeled with Cy5 and encodes enhanced green fluorescent protein, facilitating direct, sensitive analysis of mRNA localization and translation efficiency in mammalian cell models. When combined with advanced delivery systems such as those described by Ma et al., these tools enable precise assessment of mRNA uptake, intracellular trafficking, and transfection performance. For protocol optimization and troubleshooting in mRNA delivery system research, fluorescently labeled mRNA controls provide a robust foundation for reproducible assays and immune activation studies in vitro.